3315 results for «2018»
3315 results
Mastering mitral and tricuspid TEER: clinical strategies in patients with complex anatomy
17 Nov 2025 – From PCR London Valves 2025
Find out more about advanced mitral and tricuspid TEER techniques for patients with challenging anatomy. This PCR London Valves 2025 session highlights real-world approaches from the Asia Pacific region, including consensus recommendations from the Asian Pacific Society of Cardiology, strategies for simultaneous mitral TEER and left...
Late-Breaking Trials in transcatheter mitral, tricuspid and aortic interventions - Part 1
16 Nov 2025 – From PCR London Valves 2025
This session presents pivotal late-breaking trials in transcatheter mitral and aortic valve interventions. Explore one-year outcomes from the AltaValve early feasibility study featuring atrial fixation TMVR, interim results from the TARGET study assessing Cardiovalve for tricuspid regurgitation, five-year data on transapical TMVR, and outcomes of TAVI...
Meet with Myval THV series with real-world case-based learning
17 Nov 2025 – From PCR London Valves 2025
Discover the latest insights from the Myval THV series in this session from PCR London Valves 2025. Through real-world, case-based learning, the session explores lifetime management strategies for TAVI patients, the clinical relevance of intermediate and extra-large valve sizing, and the impact of foreshortening on accurate...
Mastering simple and complex LAA closure: a step-by-step case-based approach
16 Nov 2025 – From PCR London Valves 2025
This case-based session offers a comprehensive approach to mastering left atrial appendage (LAA) closure, emphasizing the critical role of imaging from pre-procedural planning through execution. It covers patient selection, procedural strategies from experienced operators, device selection tailored to anatomy, and nuanced decision-making during challenging device releases...
Beyond TAVI
16 Nov 2025 – From PCR London Valves 2025
This session offers a glimpse into cutting-edge structural heart interventions beyond TAVI. It introduces novel devices in early development stages targeting aortic valve stenosis and leaflet modification, discusses strategies to facilitate or defer TAVI, and provides opportunities for engagement with early-stage start-up partners innovating in structural...
TAVI and coronary artery disease
16 Nov 2025 – From PCR London Valves 2025
This session focuses on the interplay between TAVI and coronary artery disease, discussing high-risk TAVR cases requiring complex left main PCI with prophylactic ECMO support. It provides guidance on timing and strategies for managing concomitant coronary artery disease in TAVI patients, addressing the critical decision-making process...
TAVI: vascular complications
16 Nov 2025 – From PCR London Valves 2025
This session examines vascular complications associated with transfemoral TAVI procedures, featuring challenging cases such as initial procedural obstacles, complex post-TAVI vascular events, and unusual complications. It also explores advanced techniques like intravascular lithotripsy to optimize TAVI outcomes in patients with severe calcific iliofemoral disease.
TAVI: high coronary risk - Part 2
16 Nov 2025 – From PCR London Valves 2025
This session presents advanced strategies to mitigate high coronary risk during valve-in-valve TAVR procedures, including the LLAMACORN technique and chimney stenting to prevent coronary obstruction. It discusses management of misaligned prostheses, complex aortic and coronary anatomies, and innovative approaches such as stent crush techniques to ensure...
Complex mitral and tricuspid TEER
16 Nov 2025 – From PCR London Valves 2025
This session highlights complex cases in mitral and tricuspid transcatheter edge-to-edge repair (TEER), addressing challenges such as septal obstacles in patients with old atrial septal occluders, management of residual atrial septal defects post-mitral valve-in-ring replacement, and innovative multidisciplinary approaches. It also covers hybrid transapical mitral valve-in-valve...
Retrieval of embolised devices
16 Nov 2025 – From PCR London Valves 2025
This session delves into the complex scenarios of embolised device retrieval, exploring various interventions such as management of Lambre device embolisation, alternatives to surgery for superior vena cava baffle stent embolisation, novel strategies for chronically embolised Gore Helex atrial septal occluder device retrieval, and challenging redo...
PCR London Valves 2025 Welcome Ceremony
16 Nov 2025 – From PCR London Valves 2025
The PCR London Valves 2025 Welcome Ceremony marks the commencement of the conference, setting the stage for an immersive exploration of the latest advances and innovations in valvular heart disease management with a focus on transcatheter interventions.
Late-breaking evidence in structural and coronary interventions - Part 2
16 Nov 2025 – From PCR London Valves 2025
This session presents the latest data from pivotal late-breaking trials in interventional cardiology. Highlights include one-year results from the ADALA trial, first-in-man use of the Vivasure PerQseal Elite for large hole arterial closure, two-year outcomes of the DragonFly system in China, six-month European outcomes, and insights...
Redo TAVI with pre and post dilatation - LIVE Case
16 Nov 2025 – From PCR London Valves 2025
Watch this live case followed by a live in a box case, regarding a 93-year-old woman with hypertension, chronic bronchitis, and a history of TAVI with a Sapien 3 23 mm (2016) who presented with symptomatic severe aortic stenosis and mildly reduced LV function (50%). An...
The Silk Road of MedTech
16 Nov 2025 – From PCR London Valves 2025
Discover pioneering MedTech innovations along the Silk Road, including novel sheath designs for minimalist TAVR, self-expanding valves for pure aortic regurgitation, automated CT quantification via deep learning, and first-in-man experiences with cutting-edge valvuloplasty and TEER devices.
Innovations in TAVR: clinical insights and future perspectives
16 Nov 2025 – From PCR London Valves 2025
Presenting featured research on TAVI, this session covers outcomes from centers without on-site cardiac surgery, comparative leaflet modification techniques, conscious sedation protocols, left ventricular health in timing TAVR, and long-term valve durability insights including seven-year follow-up data.
Cutting-edge research in transcatheter tricuspid valve therapies
16 Nov 2025 – From PCR London Valves 2025
This session highlights cutting-edge research on tricuspid valve interventions, including the impact of inflow gradients on outcomes, global registry data on bicaval valve therapy, patient selection algorithms, and prognostic score validations for severe tricuspid regurgitation.
TAVI in bicuspid anatomy
16 Nov 2025 – From PCR London Valves 2025
Explore the complexities of performing TAVI in bicuspid aortic valve anatomies, with expert discussions on BASILICA tricuspidisation, procedural planning for extreme calcification, valve sizing, and challenges associated with type 0 bicuspid valves and severe calcification.
TAVI valve-in-valve
16 Nov 2025 – From PCR London Valves 2025
This session presents complex valve-in-valve TAVI cases, illustrating advanced techniques such as valve fracture and snaring in difficult anatomies, approaches for pure aortic regurgitation in degenerated surgical valves, and strategies overcoming challenges in stentless bioprostheses and previous aortic repairs.
Challenging mitral valve-in-valve
16 Nov 2025 – From PCR London Valves 2025
Gain insights into challenging mitral valve-in-valve procedures addressing small cavity anatomy, alignment difficulties, combined LAMPOON and leak closure techniques, and high-risk TMVR cases with complex left ventricular outflow tract obstruction and ECMO support.
New tricuspid valve devices
16 Nov 2025 – From PCR London Valves 2025
Examine new tricuspid valve devices and innovative procedural approaches, featuring cases of challenging anatomy with pacemaker lead repositioning, use of LuX-valve plus in massive regurgitation, position optimization in transjugular TTVR, and early clinical experiences from feasibility studies.
